<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742791</url>
  </required_header>
  <id_info>
    <org_study_id>TS134-US102</org_study_id>
    <nct_id>NCT03742791</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TS-134 Administered Orally to Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical R&amp;D Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study involving multiple dose titrations of TS-134 in healthy male and
      female subjects. The safety, tolerability and pharmacokinetics of multiple dose titrations of
      TS-134 will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2016</start_date>
  <completion_date type="Actual">December 12, 2016</completion_date>
  <primary_completion_date type="Actual">December 12, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>Day 1 to Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - Cmax</measure>
    <time_frame>Cohort 1: Day 1, Day 7, Day 8, Day 14, Cohort 2-3: Day 7, Day 14, Cohort 4-5: Day 9, Day 14, Cohort 6: Day 5, Day 14: predose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12h post-dose; Day 1 to Day 14 except above days: predose</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - AUC(0-tau)</measure>
    <time_frame>Cohort 1: Day 1, Day 7, Day 8, Day 14, Cohort 2-3: Day 7, Day 14, Cohort 4-5: Day 9, Day 14, Cohort 6: Day 5, Day 14: predose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12h post-dose; Day 1 to Day 14 except above days: predose</time_frame>
    <description>Area under the plasma concentration vs time curve over a dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - tmax</measure>
    <time_frame>Cohort 1: Day 1, Day 7, Day 8, Day 14, Cohort 2-3: Day 7, Day 14, Cohort 4-5: Day 9, Day 14, Cohort 6: Day 5, Day 14: predose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12h post-dose; Day 1 to Day 14 except above days: predose</time_frame>
    <description>Time to maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - t1/2</measure>
    <time_frame>Cohort 1: Day 1, Day 7, Day 8, Day 14, Cohort 2-3: Day 7, Day 14, Cohort 4-5: Day 9, Day 14, Cohort 6: Day 5, Day 14: predose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12h post-dose; Day 1 to Day 14 except above days: predose</time_frame>
    <description>Apparent terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - CL/F</measure>
    <time_frame>Cohort 1: Day 1, Day 7, Day 8, Day 14, Cohort 2-3: Day 7, Day 14, Cohort 4-5: Day 9, Day 14, Cohort 6: Day 5, Day 14: predose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12h post-dose; Day 1 to Day 14 except above days: predose</time_frame>
    <description>Apparent clearance following oral administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - Vd/F</measure>
    <time_frame>Cohort 1: Day 1, Day 7, Day 8, Day 14, Cohort 2-3: Day 7, Day 14, Cohort 4-5: Day 9, Day 14, Cohort 6: Day 5, Day 14: predose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12h post-dose; Day 1 to Day 14 except above days: predose</time_frame>
    <description>Apparent volumes of distribution following oral administration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TS-134</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-134</intervention_name>
    <description>5 mg to 80 mg oral solution</description>
    <arm_group_label>TS-134</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched Placebo oral solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male and female participants between 18 and 55 years of age

          -  Body weight greater than or equal to 45 kg

          -  Body Mass Index (BMI) greater than or equal to 18 and less than or equal to 30 kg/m^2

        Exclusion Criteria:

          -  Female participants who are pregnant, intend to become pregnant, or are breastfeeding

          -  Clinically significant abnormal physical examination, 12-lead electrocardiogram (ECG)
             OR cardiac telemetry prior to dosing.

          -  Significant history or presence of hepatic, renal, cardiovascular, pulmonary,
             gastrointestinal, hematological, locomotor, immunologic, ophthalmologic, metabolic or
             oncological disease.

          -  History or presence of psychiatric or neurologic disease or condition

          -  History of alcohol or drug abuse

          -  Any participant who currently uses or has used tobacco or tobacco-containing products
             for at least one month prior to screening

          -  Participated in strenuous exercise within 48 hours prior to study start (initial
             dosing) and/or are unwilling to avoid strenuous exercise at any time throughout the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisho Director</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical R&amp;D Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL - Early Phase Clinical Unit-Los Angeles</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>November 14, 2018</last_update_submitted>
  <last_update_submitted_qc>November 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TS-134, multiple dose, titration</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

